Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

AVIDART 0,5 MG CAPSULAS BLANDAS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/AVIDART 0,5 MG CAPSULAS BLANDAS

Approved

STANDARD

AVIDART 0,5 MG CAPSULAS BLANDAS

Glaxosmithkline A.E.B.E.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Nov 8, 2023
Approval ID: 2537079dd53a517b
Company: Glaxosmithkline A.E.B.E.
Type: Standard

Approval Details

Approval Id: 2537079dd53a517b
Drug Cima Aemps Name: AVIDART 0,5 MG CAPSULAS BLANDAS
Register Number: 58047-04-09-2015IP
Holder Company Name: Glaxosmithkline A.E.B.E.
Marketing Company Name: Euromed Pharma Spain S.L.
Authorization Date: 2023-11-08
Dosage Form: CÁPSULA BLANDA
Dose: 0,5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Glaxosmithkline A.E.B.E.

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Nov 8, 2023

Approval ID

2537079dd53a517b

Type

Standard

Back to CIMA-AEMPS Approvals